ASX Linkedin Twitter               

 

Dr Jennifer Rosenthal
Director of Regulatory Affairs

Dr Jennifer Rosenthal has a wealth of experience from a career spanning more than 20 years in the biotechnology sector where she has successfully managed teams and projects in the areas of clinical program management, regulatory affairs, including liaising with international regulatory agencies (e.g. US FDA, EMA) and dealing with intellectual property matters.

Prior to joining Viralytics Jennifer spent approximately 10 years at Alchemia where she was Director of Clinical and Regulatory Affairs and responsible for the management of Alchemia’s HyACT platform which included Alchemia’s late stage oncology product pipeline with multiple ongoing trials. Lead asset HA-Irinotecan proceeded to a global pivotal Phase III clinical trial for the treatment of metastatic colorectal cancer. The trial was executed under US FDA guidelines with a 505(b)(2) strategic pathway planned for approval.

Prior to Alchemia, Jennifer worked for various other Biotech companies including 5 years at Florigene where she dealt with GMO regulatory framework and their intellectual property portfolio.

Jennifer holds a doctorate in genetics and molecular biology from Monash University (Australia) and previously worked as a Post-Doctoral Research Associate at Vanderbilt University (USA).

Viralytics Limited
Suite 305, Level 3, 66 Hunter Street
Sydney NSW 2000 Australia
T: +61 (0)2 9988 4000 F: +61 (0)2 8068 6038

© Viralytics Limited 2017
This information does not take your circumstances into account. Read the relevant ASX releases, financial reports and prospectuses before making an investment decision. Shares in Viralytics Limited, ABN 12 010 657 351, are traded on the Australian Stock Exchange (ASX:VLA) and on the over-the-counter market (OTC: VRACY).